We are investigating cornea innate immunity and diabetic wound healing. Specifically, we aim to understand why diabetic patients are more susceptible to bacterial infection and what causes delayed wound healing associated with hypoglycemia. We've identified that the balance between IL-1 beta and IL-1 receptor antagonist, as well as TGF Beta-1 and TGF Beta-3, is important for corneal wound healing.
This could lead to a new treatment for diabetic care toxic. Our model may make human-delayed wound healing in diabetic patients. This allows us to study, program the cell death pathway, and develop targeted therapies.
